New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 28, 2014
05:13 EDTCTICCTI announces GOG completes enrollment in Phase 3 trial of paclitaxel poliglumex
Cell Therapeutics announced that the Gynecologic Oncology Group, or GOG, informed CTI that it has completed patient enrollment in the GOG-0212 Phase 3 clinical trial of investigational agent paclitaxel poliglumex as maintenance therapy in ovarian cancer. The trial is being conducted and managed by the GOG, which is one of the National Cancer Institute's funded cooperative cancer research groups focused on the study of gynecologic malignancies.
News For CTIC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 13, 2015
09:07 EDTCTICOn The Fly: Pre-market Movers
HIGHER: Apple (AAPL), up 1.4% after Credit Suisse upgraded Apple to Outperform and raised its iPhone volume estimates again... Best Buy (BBY), up 2.8% after being upgraded to Buy from Neutral at Goldman... SunPower (SPWR), up 2.6% after being upgraded to Outperform at Credit Suisse... Alcoa (AA), up 2% after Q4 results beat expectations. RISING AFTER GUIDANCE: Pharmacyclics (PCYC), up 17.5%... CTI BioPharma (CTIC), up 8.3%... Emulex (ELX), up 15.5%... ARIAD (ARIA), up 2.6%. LOWER: ChannelAdvisor (ECOM), down 42% following preliminary fourth quarter revenue guidance and after receiving multiple analyst downgrades... Antares Pharma (ATRS), down 7.7% after the FDA recommended that the company create a larger safety database for its clinical development program for QuickShot Testosterone.
07:50 EDTCTICCTI BioPharma sees FY15 revenue $55M-$72M, consensus $36.89M
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use